Broad-spectrum inhibition of HIV-1 by a monoclonal antibody directed against a gp120-induced epitope of CD4

PLoS ONE

Volumn 6, Issue 7, 2011, Pages

  Burastero, Samuele E ^a   Frigerio, Barbara ^b   Lopalco, Lucia ^a   Sironi, Francesca ^a   Breda, Daniela ^a   Longhi, Renato ^c   Scarlatti, Gabriella ^a   Canevari, Silvana ^b   Figini, Mariangela ^b   Lusso, Paolo ^a,d  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c CNR   (Italy)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; EPITOPE; GLYCOPROTEIN GP 120; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; OKT 4; VIRUS ENVELOPE PROTEIN; ANTISERUM; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; VIRUS ANTIGEN;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ANTIVIRAL ACTIVITY; ARTICLE; BABOON; CHIMPANZEE; CONTROLLED STUDY; DRUG POTENCY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; MACACA; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN BINDING; PROTEIN DOMAIN; T LYMPHOCYTE ACTIVATION; VIRUS CELL INTERACTION; VIRUS INHIBITION; ANIMAL; ANTIBODY PRODUCTION; CELL LINE; CELL PROLIFERATION; CHEMISTRY; COMPLEMENT FIXATION TEST; GENETICS; HYBRIDOMA; IMMUNIZATION; IMMUNOLOGY; KINETICS; MOLECULAR GENETICS; PATHOGENICITY; PATHOLOGY; PRIMATE; T LYMPHOCYTE;

HUMAN IMMUNODEFICIENCY VIRUS 1; MUS; PAN; PAPIO;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODY FORMATION; ANTIBODY SPECIFICITY; ANTIGENS, CD4; ANTIGENS, VIRAL; BASE SEQUENCE; CELL LINE; CELL PROLIFERATION; COMPLEMENT FIXATION TESTS; EPITOPES; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; HYBRIDOMAS; IMMUNE SERA; IMMUNIZATION; KINETICS; MICE; MOLECULAR SEQUENCE DATA; PRIMATES; PROTEIN BINDING; T-LYMPHOCYTES;

EID: 79960455651     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0022081     Document Type: Article

References (50)

1. Lusso P, (2006) HIV and the chemokine system: 10 years later. EMBO J 25: 447-456.
2. Wyatt R, Sodroski J, (1998) The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 280: 1884-1888.
3. Berger EA, Murphy PM, Farber JM, (1999) Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 17: 657-700.
4. Yachou A, Sekaly RP, (1999) Binding of soluble recombinant HIV envelope glycoprotein, rgp120, induces conformational changes in the cellular membrane-anchored CD4 molecule. Biochem Biophys Res Commun 265: 428-433.
5. Wu L, Gerard NP, Wyatt R, Choe H, Parolin C, et al. (1996) CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 384: 179-183.
6. Trkola A, Pomales AB, Yuan H, Korber B, Maddon PJ, et al. (1995) Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J Virol 69: 6609-6617.
7. Trkola A, Purtscher M, Muster T, Ballaun C, Buchacher A, et al. (1996) Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol 70: 1100-1108.
8. Gershoni JM, Denisova G, Raviv D, Smorodinsky NI, Buyaner D, (1993) HIV binding to its receptor creates specific epitopes for the CD4/gp120 complex. Faseb J 7: 1185-1187.
9. Xiao X, Phogat S, Shu Y, Phogat A, Chow YH, et al. (2003) Purified complexes of HIV-1 envelope glycoproteins with CD4 and CCR5(CXCR4): production, characterization and immunogenicity. Vaccine 21: 4275-4284.
10. Skinner MA, Langlois AJ, McDanal CB, McDougal JS, Bolognesi DP, et al. (1988) Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4. J Virol 62: 4195-4200.
11. Moulard M, Phogat SK, Shu Y, Labrijn AF, Xiao X, et al. (2002) Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes. Proc Natl Acad Sci U S A 99: 6913-6918.
12. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, et al. (2009) Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326: 285-289.
13. Miller N, Hutt-Fletcher LM, (1988) A monoclonal antibody to glycoprotein gp85 inhibits fusion but not attachment of Epstein-Barr virus. J Virol 62: 2366-2372.
14. Fuller AO, Spear PG, (1985) Specificities of monoclonal and polyclonal antibodies that inhibit adsorption of herpes simplex virus to cells and lack of inhibition by potent neutralizing antibodies. J Virol 55: 475-482.
15. Burastero S, Gaffi D, Lopalco L, Tambussi G, Borgonovo B, et al. (1996) Autoantibodies to CD4 in HIV type-1 exposed seronegative individuals. AIDS Research and Human Retroviruses 12: 273-280.
16. Lopalco L, Barassi C, Paolucci C, Breda D, Brunelli D, et al. (2005) Predictive value of anti-cell and anti-human immunodeficiency virus (HIV) humoral responses in HIV-1-exposed seronegative cohorts of European and Asian origin. J Gen Virol 86: 339-348.
17. Karlsson Hedestam GB, Fouchier RA, Phogat S, Burton DR, Sodroski J, et al. (2008) The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat Rev Microbiol 6: 143-155.
18. Thomas C, (2009) Roadblocks in HIV research: five questions. Nat Med 15: 855-859.
19. DeVico A, Fouts T, Lewis GK, Gallo RC, Godfrey K, et al. (2007) Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogens. Proc Natl Acad Sci U S A 104: 17477-17482.
20. Jacobson JM, Kuritzkes DR, Godofsky E, DeJesus E, Larson JA, et al. (2009) Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults. Antimicrob Agents Chemother53: 450-457.
21. Jacobson JM, Lalezari JP, Thompson MA, Fichtenbaum CJ, Saag MS, et al. Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults. Antimicrob Agents Chemother54: 4137-4142.
22. Lusso P, Cocchi F, Balotta C, Markham PD, Louie A, et al. (1995) Growth of macrophage-tropic and primary human immunodeficiency virus type 1 (HIV-1) isolates in a unique CD4+ T-cell clone (PM1): failure to downregulate CD4 and to interfere with cell-line-tropic HIV-1. J Virol 69: 3712-3720.
23. Earl PL, Cooper N, Moss B, (1991) Expression of proteins in mammalian cells using vaccinia viral vectors. In: Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, editors. Current Protocols in Molecular Biology New York John Wiley and Sons pp. 16.15.11-16.18.10.
24. Broder CC, Berger EA, (1995) Fusogenic selectivity of the envelope glycoprotein is a major determinant of human immunodeficiency virus type 1 tropism for CD4+ T-cell lines vs. primary macrophages. Proc Natl Acad Sci U S A 92: 9004-9008.
25. Salzwedel K, Smith ED, Dey B, Berger EA, (2010) Sequential CD4-coreceptor interactions in human immunodeficiency virus type 1 Env function: soluble CD4 activates Env for coreceptor-dependent fusion and reveals blocking activities of antibodies against cryptic conserved epitopes on gp120. J Virol 74: 326-333.
26. Alkhatib G, Combadiere C, Broder CC, Feng Y, Kennedy PE, et al. (1996) CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272: 1955-1958.
27. Nussbaum O, Broder CC, Berger EA, (1994) Fusogenic mechanisms of enveloped-virus glycoproteins analyzed by a novel recombinant vaccinia virus-based assay quantitating cell fusion-dependent reporter gene activation. J Virol 68: 5411-5422.
28. Fouts TR, Tuskan R, Godfrey K, Reitz M, Hone D, et al. (2000) Expression and characterization of a single-chain polypeptide analogue of the human immunodeficiency virus type 1 gp120-CD4 receptor complex. J Virol 74: 11427-11436.
29. Vita C, Drakopoulou E, Vizzavona J, Rochette S, Martin L, et al. (1999) Rational engineering of a miniprotein that reproduces the core of the CD4 site interacting with HIV-1 envelope glycoprotein. Proc Natl Acad Sci U S A 96: 13091-13096.
30. Thali M, Moore JP, Furman C, Charles M, Ho DD, et al. (1993) Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J Virol 67: 3978-3988.
31. Alexander WA, Moss B, Fuerst TR, (1992) Regulated expression of foreign genes in vaccinia virus under the control of bacteriophage T7 RNA polymerase and the Escherichia coli lac repressor. J Virol 66: 2934-2942.
32. Feng Y, Broder CC, Kennedy PE, Berger EA, (1996) HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor [see comments]. Science 272: 872-877.
33. Lane RD, Crissman RS, Lachman MF, (1984) Comparison of polyethylene glycols as fusogens for producing lymphocyte-myeloma hybrids. J Immunol Methods 72: 71-76.
34. Scarlatti G, Tresoldi E, Bjorndal A, Fredriksson R, Colognesi C, et al. (1997) In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nat Med 3: 1259-1265.
35. Figini M, Obici L, Mezzanzanica D, Griffiths A, Colnaghi MI, et al. (1998) Panning phage antibody libraries on cells: isolation of human Fab fragments against ovarian carcinoma using guided selection. Cancer Res 58: 991-996.
36. Thali M, Moore JP, Furman C, Charles M, Ho DD, et al. (1993) Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J Virol 67: 3978-3988.
37. Lusso P, Earl PL, Sironi F, Santoro F, Ripamonti C, et al. (2005) Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains. J Virol 79: 6957-6968.
38. Giudicelli V, Chaume D, Lefranc MP, (2004) IMGT/V-QUEST, an integrated software program for immunoglobulin and T cell receptor V-J and V-D-J rearrangement analysis. Nucleic Acids Res 32: W435-440.
39. Burastero SE, Figini M, Frigerio B, Lusso P, Mollica L, et al. (2009) Protective versus pathogenic anti-CD4 immunity: insights from the study of natural resistance to HIV infection. J Transl Med 7: 101.
40. Kang CY, Hariharan K, Nara PL, Sodroski J, Moore JP, (1994) Immunization with a soluble CD4-gp120 complex preferentially induces neutralizing anti-human immunodeficiency virus type 1 antibodies directed to conformation-dependent epitopes of gp120. J Virol 68: 5854-5862.
41. Celada F, Cambiaggi C, Maccari J, Burastero S, Gregory T, et al. (1990) Antibody raised against soluble CD4-rgp120 complex recognizes the CD4 moiety and blocks membrane fusion without inhibiting CD4-gp120 binding. J Exp Med 172: 1143-1150.
42. Kwong PD, Doyle ML, Casper DJ, Cicala C, Leavitt SA, et al. (2002) HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420: 678-682.
43. Denisova G, Lideman L, Spectorman E, Abulafia-Lapid R, Burke M, et al. (2003) Characterization of new monoclonal antibodies that discriminate between soluble and membrane CD4 and compete with human anti-CD4 autoimmune sera. Mol Immunol 40: 231-239.
44. Song R, Franco D, Kao CY, Yu F, Huang Y, et al. (2010) Epitope mapping of ibalizumab, a humanized anti-CD4 monoclonal antibody with anti-HIV-1 activity in infected patients. J Virol 84: 6935-6942.
45. Boon L, Holland B, Gordon W, Liu P, Shiau F, et al. (2002) Development of anti-CD4 MAb hu5A8 for treatment of HIV-1 infection: preclinical assessment in non-human primates. Toxicology 172: 191-203.
46. Burkly LC, Olson D, Shapiro R, Winkler G, Rosa JJ, et al. (1992) Inhibition of HIV infection by a novel CD4 domain 2-specific monoclonal antibody. Dissecting the basis for its inhibitory effect on HIV-induced cell fusion. J Immunol 149: 1779-1787.
47. Baldari CT, Milia E, Di Somma MM, Baldoni F, Valitutti S, et al. (1995) Distinct signaling properties identify functionally different CD4 epitopes. Eur J Immunol 25: 1843-1850.
48. Hepburn TW, Totoritis MC, Davis CB, (2003) Antibody-mediated stripping of CD4 from lymphocyte cell surface in patients with rheumatoid arthritis. Rheumatology (Oxford) 42: 54-61.
49. Choy EH, Panayi GS, Emery P, Madden S, Breedveld FC, et al. (2002) Repeat-cycle study of high-dose intravenous 4162W94 anti-CD4 humanized monoclonal antibody in rheumatoid arthritis. A randomized placebo-controlled trial. Rheumatology (Oxford) 41: 1142-1148.
50. Wang JH, Yan YW, Garrett TP, Liu JH, Rodgers DW, et al. (1990) Atomic structure of a fragment of human CD4 containing two immunoglobulin-like domains. Nature 348: 411-418.